Reconditioning Exercise for COVID-19 Patients Experiencing Residual sYmptoms
NCT ID: NCT04958161
Last Updated: 2022-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2022-01-31
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise, Sleep Quality and Nocturnal Fat Oxidation in Metabolic Syndrome
NCT04105218
Exercise Intervention in Liver Transplant Patients
NCT02367092
Exercise Training and Metabolic Flexibility in Prediabetes
NCT04051229
Resistance Training in Type 1 Diabetes Mellitus
NCT05315037
Exercise Training on Health and Medical Costs of Metabolic Syndrome Individuals.
NCT05120778
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise Therapy
Exercise therapy will be performed three times per week for 12 weeks.
Exercise Therapy
Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
Wait List Control
Wait-list-control participants will be asked to continue their normal activities over the 12 week period.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise Therapy
Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to read and speak English
* Proof of a positive nucleic acid amplification test for the determination of COVID-19
* Two months post positive nucleic acid amplification test for the determination of COVID
* Self-report of COVID-19 symptoms (symptoms include any of the following: reduced exercise capacity, fatigue, cough, shortness of breath, headache and/or joint pain)
* Able to understand and willing to sign a written informed consent document
* Willing and able to complete all study procedures including attending all exercise sessions
Exclusion Criteria
* Current use of supplemental oxygen
* Active treatment for cancer
* Severe congestive heart failure, pulmonary disease, stroke, peripheral vascular disease, coronary artery disease and/or valvular heart disease
* Positive graded exercise test
* Major psychiatric disease
* Severe liver or hepatic disease
* Uncontrolled hypertension or diabetes
* Orthopedic impairment that prevents participation in an exercise program
* Blindness
* BMI \> 40kg/m2
* Living more than 35 miles from exercise facility
* Plans to move within the next 6 months
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael J Berry, PhD
Role: PRINCIPAL_INVESTIGATOR
Wake Forest University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wake Forest University
Winston-Salem, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00075690
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.